Brief: Innate Pharma Announces Presentation Of Interim Results Of Phase 2 Tellomak Study With Lacutamab

Innate Pharma SA

22/09/2023 06:03

Sept 22 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA ANNOUNCES ENCORE PRESENTATION OF INTERIM
RESULTS
OF PHASE 2 TELLOMAK STUDY WITH LACUTAMAB WITH UPDATED OLSEN 2022
CRITERIA AT THE EORTC CUTANEOUS LYMPHOMA TUMOUR GROUP ANNUAL
MEETING 2023
    * UPDATED GLOBAL ORR OF 42.9% IN HEAVILY PRETREATED
KIR3DL2-EXPRESSINGPATIENTS WITH MYCOSIS FUNGOIDES
    * EFFICACY RESULTS CONFIRM CLINICAL ACTIVITY AND FAVORABLE
SAFETY
PROFILE OF LACUTAMAB IN ADVANCED MYCOSIS FUNGOIDES

Source text for Eikon:  ID:nBw5M8c8La 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))